Lung Cancer Liquid Biopsy

Lung Cancer Liquid Biopsy Market Outlook

The global lung cancer liquid biopsy market is poised for significant growth, projected to reach USD 5.1 billion by 2035, expanding at a CAGR of 14.5% from 2025 to 2035. This growth is largely driven by the increasing incidence of lung cancer, advancements in liquid biopsy technologies, and the growing demand for non-invasive diagnostic methods. Additionally, the rising awareness regarding early cancer detection and the benefits of personalized medicine are further propelling the market forward. The innovations in biomarker discovery and the integration of artificial intelligence in diagnostic processes are also expected to enhance the efficacy and accuracy of liquid biopsy tests, thereby bolstering market growth. Furthermore, the increasing investments in research and development from both public and private sectors are expected to introduce novel tests and technologies, fueling the overall market potential.

Growth Factor of the Market

One of the primary growth factors for the lung cancer liquid biopsy market is the escalating prevalence of lung cancer worldwide, which necessitates the development of robust diagnostic and monitoring tools. Liquid biopsies offer a non-invasive approach to detect circulating tumor cells and DNA, making them a preferred choice for both patients and healthcare providers. Moreover, the technological advancements in sequencing and bioinformatics have significantly enhanced the sensitivity and specificity of these tests, thereby attracting more patients and clinicians towards liquid biopsy solutions. Additionally, the rising aging population is contributing to the increased number of cancer cases, further driving the demand for early detection and personalized treatment options. The growing acceptance of liquid biopsy as a standard practice in oncology, paired with favorable regulatory frameworks, is likely to accelerate market growth even further.

Key Highlights of the Market

• The market is projected to reach USD 5.1 billion by 2035, with a CAGR of 14.5% from 2025 to 2035.
• Technological advancements in liquid biopsy methods are improving diagnostic accuracy and patient outcomes.
• Non-invasive nature of liquid biopsies is appealing to both patients and healthcare providers.
• Increased research funding is driving innovation in biomarker discovery.
• The growing prevalence of lung cancer is leading to a higher demand for effective monitoring and early detection solutions.

By Product Type

CTC-Based Assays:

Circulating Tumor Cell (CTC) based assays have emerged as a vital component in the lung cancer liquid biopsy market. These assays are designed to capture and analyze tumor cells that have detached from the primary tumor and entered the bloodstream. Their significance lies in their ability to provide real-time information about tumor dynamics, enabling oncologists to monitor treatment response and make informed decisions regarding therapy adjustments. Furthermore, CTC assays play a crucial role in identifying metastasis, which is pivotal for staging and prognosis in lung cancer patients. The increasing number of research studies validating the clinical utility of CTC assays is expected to drive their adoption in clinical practice, contributing to market growth.

Circulating Tumor DNA (ctDNA) Tests:

Circulating Tumor DNA (ctDNA) tests represent another critical segment of the liquid biopsy market, focusing on the genetic material released by tumor cells into the bloodstream. These tests allow for the detection of specific mutations that can guide targeted therapies, making ctDNA a valuable tool for personalized medicine. The ability to perform comprehensive genomic profiling through ctDNA testing supports oncologists in selecting the most effective treatment plans tailored to individual patients. The rising prevalence of targeted therapies and the growing emphasis on precision medicine are anticipated to further boost the demand for ctDNA tests, solidifying their position in the market.

Exosome-Based Tests:

Exosome-based tests are gaining traction in the lung cancer liquid biopsy landscape due to their efficiency in delivering molecular information about tumors. Exosomes are small vesicles secreted by cells that transport proteins, lipids, and nucleic acids, offering a rich source of biomarkers for cancer diagnosis and monitoring. These tests not only facilitate early detection of lung cancer but also enable the assessment of tumor heterogeneity and treatment resistance. The advancement in exosome isolation and characterization technologies is expected to enhance their clinical relevance, thereby driving their adoption among healthcare providers and researchers.

Others:

This category encompasses various emerging technologies and novel approaches in liquid biopsy testing, including but not limited to, protein-based assays and metabolomics. The diversification of product types reflects the ongoing research and development aimed at improving lung cancer diagnostics. As new methodologies gain traction, they are anticipated to contribute to a broader understanding of tumor biology and facilitate better patient management. The emergence of combination tests, which utilize multiple biomarkers for enhanced diagnostic accuracy, is also expected to gain prominence within this segment, further expanding the market.

By Circulating Tumor DNA

Mutational Analysis:

Mutational analysis of ctDNA is a critical aspect of lung cancer management, as it allows for the identification of specific genetic alterations that drive tumor progression. These tests facilitate the detection of actionable mutations, which can be targeted by specific therapies, thus guiding treatment decisions. The ability to monitor mutational changes over time provides insights into tumor evolution and resistance mechanisms, enabling oncologists to adjust therapeutic strategies accordingly. The growing awareness among clinicians regarding the importance of mutational profiling in personalized medicine is expected to bolster the adoption of ctDNA-based mutational analysis in lung cancer treatment.

Copy Number Alteration Detection:

Copy number alteration (CNA) detection through ctDNA analysis is another promising avenue in the liquid biopsy market. CNAs, which refer to variations in the number of copies of a particular gene, can indicate tumor progression and response to therapy. Detecting these alterations non-invasively allows for continuous monitoring of tumor dynamics and provides valuable prognostic information. As research continues to explore the relationship between CNAs and treatment outcomes, the demand for ctDNA tests that focus on this aspect is projected to rise, enhancing the overall market potential.

Gene Expression Profiling:

Gene expression profiling utilizing ctDNA is being increasingly recognized for its potential in lung cancer diagnostics. This approach measures the expression levels of various genes associated with tumor behavior, including those linked to proliferation, apoptosis, and metastasis. By analyzing gene expression patterns, clinicians can obtain insights into tumor aggressiveness and potential treatment responses. The increasing emphasis on understanding tumor microenvironments and heterogeneity highlights the relevance of gene expression profiling, paving the way for its integration into routine clinical practice.

By Application

Early Cancer Screening:

Early cancer screening is a fundamental application of liquid biopsy in lung cancer management, with the primary aim of detecting malignancies at their nascent stages when treatment is most effective. Liquid biopsies facilitate the non-invasive collection of blood samples to identify circulating tumor markers, significantly reducing the need for more invasive procedures like biopsies. This early detection capability is especially crucial for lung cancer, which often presents at advanced stages. The increasing awareness regarding the benefits of regular screening, combined with advancements in liquid biopsy technologies, is expected to drive the demand for early cancer screening applications in the coming years.

Treatment Selection:

Treatment selection is another vital application of liquid biopsies, as they provide critical information about tumor characteristics that can guide therapeutic decisions. By assessing specific biomarkers present in the bloodstream, oncologists can select targeted therapies that are more likely to yield positive outcomes for individual patients. The personalized approach to treatment not only improves efficacy but also minimizes adverse effects, enhancing the overall patient experience. As the trend toward precision medicine continues to evolve, the role of liquid biopsies in treatment selection is anticipated to become increasingly prominent.

Monitoring:

Monitoring disease progression and treatment response is one of the most critical applications of liquid biopsy in lung cancer management. Liquid biopsies enable oncologists to track changes in circulating tumor markers over time, providing real-time insights into tumor dynamics. This capability allows for the timely adjustment of treatment regimens based on the patient's specific responses, thus optimizing therapeutic efficacy. The demand for non-invasive monitoring solutions is on the rise, as they offer improved patient compliance and reduced healthcare costs compared to traditional imaging methods. Consequently, the monitoring application segment is expected to witness substantial growth in the forthcoming years.

Others:

The 'Others' category in application segments includes various niche applications of liquid biopsy, such as research initiatives aimed at exploring tumor biology and drug resistance. Ongoing research and clinical trials are expanding the understanding of how liquid biopsies can be utilized beyond the standard applications. For instance, studies are investigating the potential of liquid biopsy for assessing minimal residual disease post-treatment or predicting relapse in lung cancer patients. As new applications are developed and validated, they are expected to contribute to the overall growth of the lung cancer liquid biopsy market and further enhance its relevance in oncology.

By Sample Type

Blood:

Blood is the most commonly used sample type for liquid biopsy testing in lung cancer, thanks to its accessibility and the wealth of information it can provide. Blood samples contain a variety of biomarkers, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, making them a rich source of data for cancer diagnostics. The ease of collection, combined with advancements in techniques for isolating and analyzing these biomarkers, has solidified blood samples as the primary choice for liquid biopsies. As research continues to underscore the efficacy of blood-based liquid biopsies, this segment is projected to experience sustained growth in the market.

Urine:

Urine is emerging as a promising sample type for liquid biopsy, offering a non-invasive alternative for cancer detection. Urinary biomarkers can provide insights into tumor characteristics and disease progression, making urine-based tests a valuable tool for monitoring lung cancer patients. Although still in the early stages of development compared to blood samples, advancements in urine sample collection and analysis methodologies are expected to enhance their clinical utility. The growing emphasis on non-invasive testing options is likely to propel the demand for urine-based liquid biopsy solutions in the lung cancer market.

Saliva:

Saliva is another innovative sample type being explored in the lung cancer liquid biopsy sector. Salivary biomarkers hold the potential for non-invasive detection of lung cancer, offering a convenient and patient-friendly alternative to traditional biopsies. Recent research indicates that specific biomarkers present in saliva can correlate with the presence of lung tumors, making saliva-based tests a compelling area for development. As the field progresses, the increasing interest in utilizing saliva for liquid biopsy applications is expected to drive growth within this sample type segment.

Others:

The 'Others' category includes various unconventional sample types that are being investigated for their potential utility in liquid biopsy applications, such as pleural fluid and ascitic fluid. These samples may provide unique insights, especially in advanced lung cancer cases where traditional sample types may not yield sufficient information. Ongoing research into the use of alternative biological fluids is expected to broaden the scope of liquid biopsy applications, thereby contributing to the overall growth of the market and enhancing its clinical relevance.

By End User

Hospitals:

Hospitals are one of the primary end users of lung cancer liquid biopsy products, as they offer comprehensive oncology services to patients. The integration of liquid biopsy testing into hospital settings allows for prompt diagnosis and management of lung cancer patients, facilitating timely treatment initiation. Many hospitals are investing in liquid biopsy technologies to enhance their diagnostic capabilities and improve patient outcomes. The increasing adoption of personalized medicine within hospitals is anticipated to further drive the demand for liquid biopsy solutions, making hospitals a significant segment within the end-user category.

Diagnostic Laboratories:

Diagnostic laboratories play a critical role in the lung cancer liquid biopsy market by providing testing services that are essential for accurate diagnosis and monitoring. These facilities are equipped to perform a range of liquid biopsy assays, including CTC and ctDNA tests, contributing to the overall efficiency of cancer care. The growing reliance on specialized laboratories for complex diagnostic testing is expected to bolster their demand for liquid biopsy products. As advancements in liquid biopsy technologies continue, diagnostic laboratories are likely to enhance their service offerings, further solidifying their position as key end users in the market.

Research Institutes:

Research institutes are vital to the advancement of lung cancer liquid biopsy technologies, as they drive innovation and validate new methodologies. These institutions are often at the forefront of exploring novel biomarkers and studying their implications in lung cancer diagnostics. The collaboration between research institutes and commercial entities is essential for translating research findings into clinically applicable tests. The increasing emphasis on research and development within the oncology domain is expected to foster the growth of liquid biopsy solutions tailored for research applications, making research institutes a crucial end-user segment.

Others:

The 'Others' category includes various organizations, such as non-profit organizations and governmental health agencies, that may utilize liquid biopsy technologies for cancer research and public health initiatives. These entities often focus on population health studies and epidemiological research aimed at understanding cancer prevalence and risk factors. The growing interest in liquid biopsies for public health applications is expected to drive demand within this segment, contributing to the overall expansion of the lung cancer liquid biopsy market.

By Region

The North American region holds a prominent position in the lung cancer liquid biopsy market, accounting for approximately 45% of the global market share in 2025. The growth trajectory in this region is supported by the increasing prevalence of lung cancer, robust healthcare infrastructure, and significant investments in research and development. Furthermore, the presence of major players in the liquid biopsy space, along with a favorable regulatory environment, fuels innovation and adoption of advanced diagnostic solutions. The North American market is projected to grow at a CAGR of 15.2% from 2025 to 2035, reflecting the region's commitment to improving cancer diagnostics and patient outcomes.

Europe is also a significant market for lung cancer liquid biopsies, contributing around 30% of the global market share in 2025. The region's growth is driven by the rising awareness of cancer screening programs, advancements in liquid biopsy technologies, and an increasing number of collaborations between academic institutions and industry players. Countries such as Germany, the UK, and France are leading the charge in adopting liquid biopsy solutions for early cancer detection and treatment monitoring. The European market is forecasted to experience a CAGR of 13.8% from 2025 to 2035, as healthcare providers increasingly integrate liquid biopsy tests into clinical practice.

Opportunities

With the lung cancer liquid biopsy market on the rise, numerous opportunities are emerging for companies and researchers alike. One promising avenue is the continuous improvement in liquid biopsy technologies, which is likely to yield more sensitive and specific tests. As the understanding of tumor biology evolves, the potential for identifying novel biomarkers through liquid biopsy methodologies is expanding, offering the prospect of enhanced diagnostic capabilities. Additionally, the integration of artificial intelligence and machine learning into liquid biopsy analysis could facilitate the interpretation of complex data, streamlining the diagnostic process and improving clinical decision-making. Such advancements are likely to create a competitive landscape in which innovative companies can flourish and drive growth within the market.

Furthermore, the increasing focus on personalized medicine and the rising demand for non-invasive diagnostic methods are projected to fuel market expansion. Healthcare providers are increasingly recognizing the significance of early cancer detection and treatment monitoring, and liquid biopsy presents a viable solution for achieving these goals. The growing patient population seeking minimally invasive options is likely to stimulate demand for liquid biopsy tests. Additionally, collaboration between pharmaceutical companies and diagnostic organizations can pave the way for the development of companion diagnostics, further enhancing the utility of liquid biopsies in targeted therapies. As the market continues to evolve, organizations that capitalize on these opportunities are well-positioned for substantial growth.

Threats

While the lung cancer liquid biopsy market shows significant promise, there are several threats that could hinder its growth trajectory. One major threat is the presence of stringent regulatory requirements and varying approval processes across different regions. Navigating the complex landscape of regulatory approvals can be a time-consuming and costly endeavor for companies seeking to bring their products to market. Additionally, there exists a risk of market saturation as various players enter the liquid biopsy space, potentially leading to increased competition and price pressure. This overcrowding could reduce profit margins, making it challenging for smaller companies to sustain their operations. Furthermore, skepticism from certain oncologists regarding the reliability and clinical utility of liquid biopsies may impede their widespread adoption in clinical practice, posing another barrier to market growth.

Additionally, the potential for technological obsolescence represents a threat in the rapidly evolving landscape of liquid biopsy. As new technologies are developed and existing ones are refined, companies that fail to innovate may find themselves at a competitive disadvantage. Therefore, continuous investment in research and development is essential to keep pace with advancements in the field. Lastly, the rising costs associated with liquid biopsy testing and the overall economic burden of cancer care could deter some patients and healthcare providers from utilizing these diagnostic solutions, thereby limiting market potential. Addressing these threats requires strategic planning and adaptability from market participants.

Competitor Outlook

• Guardant Health, Inc.
• Foundation Medicine, Inc.
• GRAIL, Inc.
• Exact Sciences Corporation
• Roche Diagnostics
• Biocept, Inc.
• Menarini Silicon Biosystems
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• QIAGEN N.V.
• Personal Genome Diagnostics, Inc.
• Avant Diagnostics, Inc.
• Cynvenio Biosystems, Inc.

The competitive landscape of the lung cancer liquid biopsy market is characterized by a diverse array of players, ranging from established diagnostic companies to biotechnology startups. The presence of major corporations such as Guardant Health, Foundation Medicine, and Roche Diagnostics highlights the industry's commitment to advancing non-invasive cancer diagnostics. These companies have invested heavily in research and development to bring innovative liquid biopsy solutions to market, facilitating early detection and effective monitoring of lung cancer. The competitive environment is further intensified by collaborations between various players, including pharmaceutical companies and diagnostic technology providers, aimed at integrating liquid biopsy into standard oncology practice.

Established companies like Exact Sciences and Illumina are prominent in the market, boasting a strong portfolio of liquid biopsy products and a robust distribution network. Their ability to leverage existing relationships with healthcare providers and clinical laboratories positions them favorably in the competitive landscape. Furthermore, these companies continually invest in expanding their product offerings and improving the accuracy and efficiency of their liquid biopsy tests. As the market evolves, the competition among these key players is expected to drive innovation and lead to the development of more advanced testing solutions tailored to the varying needs of oncologists and patients.

Additionally, up-and-coming companies like GRAIL and Biocept are making significant strides in the liquid biopsy domain by developing cutting-edge technologies and assays that address specific clinical challenges. The agility of smaller firms enables them to respond quickly to emerging trends and unmet needs in the market. These companies often focus on niche applications, which can lead to innovative solutions that differentiate them from larger competitors. The interplay between established players and emerging companies is likely to shape the future trajectory of the lung cancer liquid biopsy market, driving continuous advancements and enhancing the overall standard of care for lung cancer patients.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GRAIL, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Biocept, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sysmex Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Guardant Health, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Avant Diagnostics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 F. Hoffmann-La Roche AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cynvenio Biosystems, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Foundation Medicine, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Exact Sciences Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Menarini Silicon Biosystems
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Personal Genome Diagnostics, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Lung Cancer Liquid Biopsy Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Lung Cancer Liquid Biopsy Market, By Application
    • 6.2.1 Early Cancer Screening
    • 6.2.2 Treatment Selection
    • 6.2.3 Monitoring
    • 6.2.4 Others
  • 6.3 Lung Cancer Liquid Biopsy Market, By Sample Type
    • 6.3.1 Blood
    • 6.3.2 Urine
    • 6.3.3 Saliva
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Lung Cancer Liquid Biopsy Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Lung Cancer Liquid Biopsy market is categorized based on

By Application

• Early Cancer Screening
• Treatment Selection
• Monitoring
• Others

By Sample Type

• Blood
• Urine
• Saliva
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Guardant Health, Inc.
• Foundation Medicine, Inc.
• GRAIL, Inc.
• Exact Sciences Corporation
• Roche Diagnostics
• Biocept, Inc.
• Menarini Silicon Biosystems
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• QIAGEN N.V.
• Personal Genome Diagnostics, Inc.
• Avant Diagnostics, Inc.
• Cynvenio Biosystems, Inc.